Small Caps News
Arecor granted first US patent for insulin formulations
Biopharmaceutical company Arecor Therapeutics announced on Wednesday that the United States Patent and Trademark Office has granted a patent protecting novel formulations of its proprietary insulin products, ‘AT247’ and ‘AT278’.
Futura signs up Korean partner for erection gel product
Pharmaceutical and drug delivery technology developer Futura Medical has entered into a licensing agreement with Menarini Korea, it announced on Wednesday, for the exclusive rights to commercialise the company's topical gel-based erectile dysfunction treatment MED3000 in South Korea.
GENinCode inks collaboration with largest US medical school
Cardiovascular genetics company GENinCode announced a collaboration with the Indiana University School of Medicine (IU) on Wednesday - the largest medical school in the United States.
Europa Metals upbeat on latest testing at Toral
Lead, zinc and silver developer Europa Metals announced positive results from x-ray transmission (XRT) ore sorting test work at the Toral project in Spain on Wednesday.
4basebio launches two new synthetic DNA products
Cell and gene therapy developer 4basebio announced the expansion of its synthetic DNA product offering on Wednesday.
MaxCyte reports record Q4 and full-year revenue
Cell engineering company MaxCyte reported record quarterly revenue of $10. 2m (£7. 73m) for the final three months of 2021 on Wednesday, up 19% year-on-year.
WANdisco locks in new $1.5m contract
Software company WANdisco has secured a $1. 5m contract win with an unnamed telecommunications company.
James Cropper downgrades FY pre-tax profit guidance
Advanced materials and paper products group James Cropper downgraded full-year profits guidance on Wednesday as a result of the impact of worldwide wholesale gas price rises.
Renewi FY trading seen ahead of previous expectations
Waste-to-product business Renewi said on Wednesday that overall trading for the year ending 31 March has "remained strong", with the group now expecting its full-year performance to be ahead of previous expectations.